Norges Bank
AVIR icon

Norges Bank’s Atea Pharmaceuticals AVIR Stock Holding History

Norges Bank’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-36,200
Closed -$146K – 1935
2024
Q1 		$146K Hold
36,200
– – ﹤0.01% 1873
2023
Q4 		$110K Hold
36,200
– – ﹤0.01% 1937
2023
Q3 		$109K Sell
36,200
-700
-2% -$2.38K ﹤0.01% 1958
2023
Q2 		$138K Sell
36,900
-167,300
-82% -$626K ﹤0.01% 2000
2023
Q1 		$684K Hold
204,200
– – ﹤0.01% 2031
2022
Q4 		$982K Buy
+204,200
New +$1.03M ﹤0.01% 2058
2022
Q1 		– Sell
-109,095
Closed -$975K – 2173
2021
Q4 		$975K Hold
109,095
– – ﹤0.01% 2111
2021
Q3 		$3.83M Sell
109,095
-537,267
-83% -$14.9M ﹤0.01% 1964
2021
Q2 		$13.9M Buy
+646,362
New +$19.4M ﹤0.01% 1679
2021
Q1 		– Sell
-30,000
Closed -$1.25M – 2136
2020
Q4 		$1.25M Buy
+30,000
New +$967K ﹤0.01% 2005

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Norges Bank's AVIR Position: Q2 2024 in Review

Norges Bank sold out of Atea Pharmaceuticals (AVIR) in Q2 2024, closing a stake of 36,200 shares — an estimated $146K sold.

Norges Bank first reported a position in AVIR in Q4 2020 and held it in 10 quarters. The position peaked at $13.9M in Q2 2021. 105 funds tracked by Wall St. Rank hold AVIR as of Q2 2024.

  • Norges Bank reported no remaining Atea Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Norges Bank sold 36,200 Atea Pharmaceuticals shares in Q2 2024, an estimated $146K.
  • Norges Bank first reported a position in Atea Pharmaceuticals in Q4 2020 and held it in 10 quarters.
  • Norges Bank's Atea Pharmaceuticals position peaked at $13.9M in Q2 2021.
  • 105 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2024.

Based on Norges Bank's 13F filing for Q2 2024, filed 14 Aug 2024.